['clostridium difficile infection']
['ridinilazole', 'fidaxomicin']

        Inclusion Criteria:

          -  Informed Consent

          -  Clinical diagnosis of CDI plus laboratory diagnostic test

          -  No more than 30 hours antimicrobial treatment for current CDI episode

          -  Female subjects of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  Life-threatening or fulminant CDI

          -  Subjects with 2 or more episodes of CDI in the previous year

          -  Females who are pregnant or breastfeeding

          -  History of inflammatory bowel disease

          -  Co-administration of potent P-glycoprotein inhibitors

          -  Participation in other Clinical research studies within one month of screening

          -  Subjects that the Investigator feels are inappropriate for the study
      